Latest news

Thumbnail image for EMA advisors back eight medicines for approval

EMA advisors back eight medicines for approval

Eight medicines have been backed for approval by the European Medicines Agency’s Committee for Medicinal Products for Human Use, including new therapies to treat hepatitis C, multiple sclerosis and cancer.

26th June 2017

Thumbnail image for US approval for Portola’s BevyxXa

US approval for Portola’s BevyxXa

Portola Pharmaceuticals’ BevyxXa has been cleared by the US Food and Drug Administration for preventing blood clots in hospitalised patients.

26th June 2017

Thumbnail image for ABPI suspends Astellas UK for a further year

ABPI suspends Astellas UK for a further year

Astellas UK’s membership of the Association of the British Pharmaceutical Industry has been suspended for a further 12 months because of a number of “serious breaches” of the Code of Practice.

23rd June 2017

Thumbnail image for NICE turnaround for AstraZeneca’s COPD drug Daxas

NICE turnaround for AstraZeneca’s COPD drug Daxas

AstraZeneca’s Daxas is now likely to be routinely available on the NHS to patients with chronic obstructive pulmonary disease (COPD), after new evidence helped persuade cost regulators that the drug is value for money in this setting.

23rd June 2017

Thumbnail image for US nod for CSL Behring’s HAE prevention therapy

US nod for CSL Behring’s HAE prevention therapy

US regulators have approved CSL Behring’s Haegarda, the first C1 esterase inhibitor for subcutaneous administration to prevent hereditary angioedema (HAE) attacks in adolescent and adults

23rd June 2017

Previous  --   1 2 3 4 5 6 7 8 9 10   --  Next

Latest jobs

View all

Download our apps

Go to the App Store or Google Play and search for 'PharmaTimes' to download our free app.

Go to the App Store or Google Play and search for 'PharmaTimes' to download our free app.

Download